Turning Innovation into Impact
CureAge Therapeutics emerged from the partnership between the Children’s Tumor Foundation’s and Deep Science Ventures to identify the highest impact solution for NF patients and investors.
2022
June
Start of Partnership
2023
ㅤ
Opportunity Area Defined
2024
ㅤ
Team and Strategy Consolidation
2024
December
Investment Committee Approval
2025
January
Company Launch
%201.png)
The result:
A delivery platform targeting Schwann cells, with NF1 peripheral tumors as the initial indication to demonstrate its curative potential
Investors
